GenEdit

GenEdit is developing safe and efficient gene editing. Delivery remains a major challenge for gene editing therapies and limits the therapies’ performance. To improve delivery, GenEdit has developed a delivery platform called NanoGalaxy, which contains a library of unique non-viral, non-lipid, polymer nanoparticles that can be used as vectors for gene therapies. Polymer backbones are combined with small molecules to create a vast polymer diversity which GenEdit screens. Diversity in charge, size and composition offers a unique array of properties that affect the tissue-targeting specificity and durability. GenEdit is primarily interested in the lung, CNS and immune system for tissue targeting. By targeting these tissues selectively, GenEdit aids in the development of therapeutics for patients with high unmet medical need.